Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes

Abstract

The therapeutic landscape for obesity and type 2 diabetes mellitus (T2DM) is being reshaped by glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Orforglipron (LY3502970) represents a significant evolution in this class. Given the limitations of injectable GLP-1 RAs and the administration constraints of oral semaglutide, orforglipron offers a major convenience advantage: it is a small molecule with ~79% oral bioavailability that requires no food or water restrictions. Mechanistically, it acts by stimulating cyclic adenosine monophosphate without inducing β-arrestin recruitment, thus potentially limiting receptor desensitization and tachyphylaxis. Phase 3 trials demonstrated potent, dose-dependent efficacy. In the ACHIEVE-3 head-to-head trial (T2DM), orforglipron 36 mg proved superior to oral semaglutide 14 mg, delivering significantly greater reductions in hemoglobin A1c (–2.2% vs –1.4%) and body weight (–9.2% vs –5.3%). In the ATTAIN-2 trial (obesity and T2DM), the same dose achieved 10.5% mean weight loss. The safety profile is consistent with the GLP-1 RA class, dominated by manageable gastrointestinal events mitigated by slow dose escalation. A nondose-dependent heart rate increase and a small signal for mild pancreatitis were observed. A class-specific concern exists regarding increased ventricular arrhythmia risk in patients with heart failure with reduced ejection fraction treated with conventional GLP-1 RAs.

Overview

Integrity signals

Registry

Crossref · 10.1097/crd.0000000000001139

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 57 references

Research works printed but not linked: 2

  1. Emmerich, 2024, Obesity and severe obesity prevalence in adults: United States, August 2021–August 2023., NCHS Data Brief
  2. Anderer, 2025, FDA approves tirzepatide as first drug for obstructive sleep apnea., JAMA, 333, 656

Cited by

See all 7

Metadata

Authors
Pillai, A. A., Sharma, A. M., Krayem, H., Frishman, W. H., & Aronow, W. S.
Affiliations
  • Virginia Commonwealth University (US)
  • Yale New Haven Hospital (US)
  • Westchester Medical Center (US)
Corresponding author
  • Pillai, Ashwin A.
  • Krayem, Hussein
Venue
Cardiology in Review
Published
2025-12-16
ISSN
  • 1061-5377 (ISSN-L)
  • 1538-4683
OpenAlex
W4417350225
Cited by
3
References
57
Citations by year
2026: 3
FWCI
2.06
Type
journal article
Language
en
Open access
closed
Locations
  • Cardiology in Review (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
orforglipron, oral GLP-1 receptor agonists, obesity, type 2 diabetes, semaglutide, oral bioavailability, cAMP signaling, beta-arrestin, receptor desensitization, tachyphylaxis, glycemic control, weight loss, gastrointestinal adverse effects, heart rate increase, pancreatitis, ventricular arrhythmias, heart failure with reduced ejection fraction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes. https://app.cochat.ai/papers/10.1097/crd.0000000000001139
The paper
Pillai, A. A., Sharma, A. M., Krayem, H., Frishman, W. H., & Aronow, W. S. (2025). Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes. Cardiology in Review. https://doi.org/10.1097/crd.0000000000001139

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.